Zollinger‑Ellison Disease (Type II) – Complete Patient Guide

Overview

Zollinger‑Ellison disease (ZED) is a rare, chronic condition in which one or more gastrin‑producing neuroendocrine tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and malabsorption.

There are two clinical classifications:

• Type I (sporadic) – isolated gastrinoma without evidence of widespread disease.
• Type II (associated with multiple endocrine neoplasia type 1, MEN‑1) – gastrinomas occurring as part of the MEN‑1 syndrome, which also includes parathyroid and pituitary tumors.

Type II accounts for roughly 10–20 % of all Zollinger‑Ellison cases and is most often diagnosed in adults aged 30–60 years. Men and women are affected equally.

Prevalence*: estimated 1–3 cases per million population worldwide (Mayo Clinic; NIH).

Symptoms

Because excess gastric acid damages the gastrointestinal (GI) tract, the symptom pattern can be varied and sometimes mimics other ulcer diseases. Common symptoms include:

Gastro‑intestinal ulcer disease

• Recurrent or refractory peptic ulcers – often multiple, located beyond the duodenum (i.e., jejunal ulcers), and resistant to standard ulcer therapy.
• Abdominal pain – burning or gnawing pain that may improve after eating (due to ulcer “buffering”) or worsen with meals if acid load is high.
• Vomiting – may contain blood (hematemesis) if an ulcer erodes a vessel.
• Food intolerance – patients may avoid meals to lessen pain.

Secretory diarrhea

• Watery, fat‑laden (steatorrhea) stools occurring 3–5 times per day.
• Weight loss despite normal or increased appetite.

Malabsorption & nutritional deficits

• Deficiency of fat‑soluble vitamins (A, D, E, K) leading to fatigue, bruising, or night blindness.
• Iron‑deficiency anemia from chronic GI blood loss.

Systemic signs

• Fatigue, weakness, and generalized malaise.
• Occasional low‑grade fever.

MEN‑1 specific features (Type II)

• Hyperparathyroidism – kidney stones, bone pain.
• Pituitary adenomas – headaches, visual field defects, hormonal imbalances.

Causes and Risk Factors

Type II ZED is fundamentally linked to the genetic disorder multiple endocrine neoplasia type 1 (MEN‑1). MEN‑1 is caused by germline mutations in the MEN1 tumor suppressor gene, which encodes the protein menin. Loss of menin function predisposes cells of the endocrine pancreas, parathyroid, and pituitary to tumor formation.

Key risk factors

• Inherited MEN‑1 mutation – autosomal dominant; each child of an affected parent has a 50 % chance of inheriting the mutation.
• Family history of MEN‑1 – up to 40 % of patients with ZED type II have a first‑degree relative with MEN‑1.
• Age – most diagnoses occur between 30 and 60 years.
• Gender – no strong sex predilection, though some studies suggest slightly higher detection in women because of earlier endocrine work‑ups.
• Environmental factors – none have been definitively linked, but chronic H. pylori infection may worsen ulcer disease in these patients.

Diagnosis

Diagnosing ZED type II involves confirming hypergastrinemia, demonstrating acid hypersecretion, and locating the gastrinoma(s). A multidisciplinary approach (gastroenterology, endocrinology, surgery, radiology) is essential.

Laboratory tests

• Fasting serum gastrin level – values > 1000 pg/mL are highly suggestive; levels 2–3 × upper limit of normal after a secretin stimulation test are diagnostic (American Gastroenterological Association).
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase) confirms gastrinoma.
• Acid output measurement – basal acid output > 15 mEq/h or maximal output > 30 mEq/h supports diagnosis.
• MEN‑1 genetic testing – DNA sequencing of the MEN1 gene, recommended for all patients with type II disease or a family history.

Imaging studies

• Endoscopic ultrasound (EUS) – high sensitivity (≈ 85 %) for detecting small pancreatic or duodenal gastrinomas.
• Multiphasic contrast‑enhanced CT or MRI – identifies larger lesions and assesses metastatic spread to liver or lymph nodes.
• Somatostatin receptor scintigraphy (Octreoscan®) or ^68Ga‑DOTATATE PET/CT – highly sensitive for neuroendocrine tumors, especially when lesions are < 1 cm.
• Selective arterial secretin injection (SASI) test – invasive but can localize occult gastrinomas when non‑invasive imaging is inconclusive.

Pathology

If surgical resection is performed, histopathology confirms a well‑differentiated neuroendocrine tumor with immunohistochemical positivity for gastrin and chromogranin A.

Treatment Options

Treatment aims to control acid hypersecretion, remove or reduce tumor burden, and manage MEN‑1 related manifestations.

Medical therapy – acid control

• High‑dose proton pump inhibitors (PPIs) – omeprazole 60 mg daily or equivalent; most effective at suppressing gastric acid. Long‑term use is generally safe but monitor for B12 deficiency, hypomagnesemia, and bone density loss.
• H2‑receptor antagonists – cimetidine or ranitidine (if PPIs contraindicated), often combined with PPIs for refractory cases.
• Potassium‑competitive acid blockers (e.g., vonoprazan) – emerging options with rapid, potent acid suppression; not yet FDA‑approved for ZED but used off‑label in some centers.

Surgical management

• Curative resection – enucleation or pancreaticoduodenectomy (Whipple) for localized gastrinomas. Success rates 70‑80 % when tumors are < 2 cm and no metastasis.
• Liver metastasis treatment – hepatic resection, radiofrequency ablation, or hepatic arterial embolization.
• Debulking surgery – reduces tumor mass when cure is unlikely, improving symptom control.

Systemic therapies for unresectable/metastatic disease

• Somatostatin analogs (SSA) – octreotide or lanreotide inhibit gastrin release and may stabilize tumor growth.
• Targeted therapy – everolimus (mTOR inhibitor) approved for progressive pancreatic neuroendocrine tumors.
• Peptide‑receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor–positive cells; improves progression‑free survival.
• Chemotherapy – streptozocin‑based regimens for high‑grade or rapidly progressive disease.

Management of MEN‑1 manifestations

• Parathyroidectomy for hyperparathyroidism.
• Transsphenoidal surgery or medical therapy for pituitary adenomas.

Lifestyle and supportive measures

• Small, frequent meals; avoid foods that provoke acid (spicy, caffeinated, alcoholic).
• Calcium and vitamin D supplementation if on long‑term PPIs.
• Regular bone density testing.
• Vaccinations for hepatitis B & C if liver disease is present.

Living with Zollinger‑Ellison Disease (Type II)

Given the chronic nature of ZED and its association with MEN‑1, a proactive, multidisciplinary plan improves quality of life.

Medication adherence

• Take PPIs exactly as prescribed; never skip doses, even if symptoms improve.
• Set reminders or use pill organizers.

Nutrition

• Consume a balanced diet rich in lean protein, whole grains, and low‑fat dairy.
• Consider a dietitian experienced with malabsorption to tailor fat‑soluble vitamin supplementation.
• Stay hydrated; replace electrolytes lost with diarrhea.

Monitoring

• Serum gastrin and acid output every 6–12 months.
• Annual imaging (MRI or CT) to detect new gastrinomas or metastases.
• Screen for MEN‑1 complications: serum calcium & PTH every 1–2 years; pituitary MRI every 3–5 years.

Psychosocial support

• Join support groups (e.g., Rare Tumor Network, MEN‑1 Foundation).
• Consider counseling for anxiety or depression that may accompany chronic illness.

Work and daily activities

• Most patients can maintain regular employment with medication control.
• Inform employers about potential need for medication breaks.
• Avoid high‑stress situations that may exacerbate ulcer pain.

Prevention

Because ZED type II is genetically driven, primary prevention is limited. However, the following measures can reduce disease burden:

• Genetic counseling for families with known MEN‑1 mutations; offers testing for at‑risk relatives.
• Early screening – annual gastrin level measurement and imaging for asymptomatic MEN‑1 carriers starting in adolescence.
• Lifestyle – smoking cessation and limiting alcohol reduce ulcer risk and improve overall GI health.
• Eradicate H. pylori if present, as co‑infection worsens ulcer disease.

Complications

If untreated or inadequately controlled, Zollinger‑Ellison disease can lead to serious health problems:

• Perforated duodenal or jejunal ulcer – surgical emergency with risk of peritonitis.
• Upper GI bleeding – melena or hematemesis requiring endoscopic or surgical intervention.
• Severe malabsorption – leading to osteopenia/osteoporosis, anemia, and protein‑energy wasting.
• Electrolyte disturbances – hypokalemia, metabolic alkalosis from chronic diarrhea.
• Liver metastases – can cause hepatic insufficiency, portal hypertension.
• Secondary cancers – MEN‑1 patients have heightened risk for pancreatic adenocarcinoma and other endocrine tumors.
• Drug‑related complications – long‑term PPI use may increase risk of Clostridioides difficile infection and gastric fundic gland polyps.

When to Seek Emergency Care

Prompt medical attention can prevent life‑threatening complications and improve outcomes.

---

References (selected):

• Mayo Clinic. “Zollinger‑Ellison syndrome.” Mayo Clinic Proceedings, 2023.
• National Institutes of Health. “Multiple Endocrine Neoplasia Type 1.” NIH Genetic and Rare Diseases Information Center, 2022.
• American Gastroenterological Association. “Guidelines for the Diagnosis and Management of Gastric Acid Hypersecretory Disorders.” 2021.
• World Health Organization. “Classification of Neuroendocrine Tumors.” WHO, 2022.
• Cleveland Clinic. “Peptide‑Receptor Radionuclide Therapy for Neuroendocrine Tumors.” 2023.
• European Neuroendocrine Tumor Society (ENETS). “Consensus Guidelines for MEN‑1 Management.” 2022.